Endo Ldl Goal Less Than 70 T2d

---
name: endo-ldl-goal-less-than-70-t2d
description: Recommends lowering LDL-C to <70 mg/dL in adults with type 2 diabetes and cardiovascular risk factors to reduce ASCVD risk. Consider when encountering a patient with T2D and CV risk factors, LDL-C >70 mg/dL requiring treatment, or when assessing lipid-lowering therapy goals in diabetes.
---

# LDL-C goal less than 70 mg/dL for type 2 diabetes

## STEP 1 — Gather Information
Collect: type 2 diabetes diagnosis, cardiovascular risk factors (traditional: age ≥40, hypertension, smoking, family history of premature ASCVD; risk-enhancing: elevated Lp(a) ≥50 mg/dL, CKD, metabolic syndrome, albuminuria), current LDL-C level, current lipid-lowering therapy, lifestyle modifications, renal function, pregnancy status. Action: Proceed to assess whether the patient has T2D and cardiovascular risk factors.

## STEP 2 — Rule In / Rule Out
Does the patient have type 2 diabetes mellitus and at least one cardiovascular risk factor? If yes, proceed to evaluate LDL-C goal; if no, the LDL-C <70 mg/dL goal does not apply (consider alternative lipid management per other guidelines). Action: If yes, go to Step 3; if no, stop here and follow general lipid management.

## STEP 3 — Classify or Stratify
Classify cardiovascular risk: high risk if established ASCVD or multiple risk factors (≥2 traditional risk factors or risk-enhancing factors); moderate risk if T2D with risk factors but no established ASCVD and fewer than multiple risk factors. Action: For high risk, consider LDL-C goal <55 mg/dL; for moderate risk, LDL-C goal <70 mg/dL.

## STEP 4 — Decide
If LDL-C is above the applicable goal (<70 mg/dL for moderate, <55 mg/dL for high risk), initiate lifestyle modification plus statin therapy; if LDL-C remains above goal despite maximally tolerated statin, add ezetimibe or PCSK9 inhibitor; if triglycerides 150–499 mg/dL with residual hypertriglyceridemia on statin, consider adding 4 g/day EPA ethyl ester. Action: Implement lipid-lowering regimen per classification.

## Clinical Guardrails / Mimics / Pitfalls
Do not initiate statin therapy in pregnancy or if planning pregnancy; select statin based on renal clearance (pitavastatin, pravastatin, rosuvastatin preferred in CKD); monitor for myopathy, especially with drugs interacting via CYP3A4; do not rely on LDL-C alone when triglycerides >500 mg/dL (use non-HDL-C or apoB); avoid fibrates if triglycerides >500 mg/dL; do not use niacin due to limited benefit and safety concerns.

## Concrete Clinical Example
A 58-year-old man with type 2 diabetes, hypertension, and LDL-C 110 mg/dL has no prior ASCVD. He has moderate risk; goal LDL-C <70 mg/dL. Lifestyle changes and moderate-intensity statin (atorvastatin 20 mg) are started; LDL-C drops to 68 mg/dL, meeting goal.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, DOI:10.1210/clinem/dgaa674

> **TODO:** consider adding scripts/calc.py for the endo-ldl-goal-less-than-70-t2d calculator